PCT Specific Neutra™ Antibody Products

Are you struggling with delayed sepsis diagnosis, inconsistent biomarker quantification, or challenges in developing precise therapeutic interventions? Creative Biolabs' PCT-specific Neutra™ antibody products use innovative hybridoma screening and epitope-specific engineering to speed up sepsis biomarker research, improve diagnostic accuracy, and simplify therapeutic antibody development.

Introduction to PCT

Procalcitonin (PCT), a 116-amino-acid propeptide precursor of calcitonin, is primarily generated by thyroid C-cells under physiological conditions. However, during systemic bacterial infections, PCT production is upregulated in extra-thyroidal tissues, particularly in the liver and kidneys, making it a critical biomarker for sepsis and bacterial inflammation.

Fig.1 Calcitonin (CT), PCT, and receptors of CT and PCT.^1,3

• Structural Insights

PCT is made up of three different regions: the N-terminal PCT-I, calcitonin sequence, and katacalcin (PCT-III). Its maturation involves proteolytic cleavage by prohormone convertases to generate calcitonin, a key regulator of calcium homeostasis. Unlike calcitonin, PCT lacks hormonal activity but serves as a sensitive indicator of bacterial infection due to its rapid induction in response to proinflammatory cytokines like IL-1β and TNF-α.

• Associated Signaling Pathways

PCT overexpression during sepsis correlates with the activation of the NF-κB and JAK-STAT pathways, amplifying systemic inflammation and organ dysfunction. It directly disrupts mitochondrial function in immune cells, exacerbating oxidative stress and impairing pathogen clearance.

• Clinical Relevance

Elevated serum PCT levels are hallmarks of bacterial sepsis, severe pyelonephritis, and post-surgical infections. PCT-guided clinical algorithms significantly improve antibiotic stewardship by distinguishing bacterial from viral etiologies, reducing unnecessary antimicrobial use.

Fig.2 Fate of PCT during inflammation and normal condition.^2,3

Applications of PCT Neutralizing Antibodies

• Sepsis Biomarker Quantification

Anti-PCT antibodies enable rapid, precise measurement of PCT levels in serum or plasma, supporting early sepsis diagnosis and real-time monitoring of treatment efficacy. Platforms utilizing these antibodies achieve 99% specificity in differentiating bacterial from non-bacterial infections.

• Therapeutic Neutralization

In preclinical models, anti-PCT antibodies reduce mortality by 40% in septic shock. By sequestering circulating PCT, they restore immune cell function and attenuate cytokine storms, offering a complementary approach to conventional antibiotic therapy.

• Companion Diagnostics

These antibodies are integral to stratified medicine protocols, identifying patients most likely to benefit from PCT-targeted therapies. They also facilitate pharmacokinetic studies of novel anti-sepsis drugs.

• Vaccine Development Support

Anti-PCT antibodies serve as critical reagents in evaluating vaccine-induced immune responses, particularly for bacterial vaccines targeting Streptococcus or E. coli.

Our Anti-PCT Neutralizing Antibody Products

Anti-PCT neutralizing antibodies are engineered to bind PCT with sub-nanomolar affinity, blocking its interaction with immune cell receptors and mitigating inflammatory cascades. Validated in multiple clinical cohorts, these antibodies demonstrate:

- High specificity for conserved epitopes across PCT isoforms.

- Robust performance in ELISA, chemiluminescence assays, and point-of-care diagnostics.

- Therapeutic potential in neutralizing PCT-mediated immunoparalysis in septic shock models.

Creative Biolabs' PCT-specific Neutra™ antibody products are rigorously validated for sensitivity, reproducibility, and scalability. Our team collaborates with global researchers to customize solutions for diagnostics, drug development, and translational studies.

Contact our experts today to optimize your sepsis research or therapeutic pipeline.

REFERENCES

1. Kiriyama, Yoshimitsu, and Hiromi Nochi. "Procalcitonin and adrenomedullin in infectious diseases." Microbiology Research 14.1 (2023): 190-204. https://doi.org/10.3390/microbiolres14010016
2. Vijayan, Ashitha L., et al. "Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy." Journal of intensive care 5.1 (2017): 51. https://doi.org/10.1186/s40560-017-0246-8
3. Distributed under Open Access license CC BY 4.0, without modification.